KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Chengming LiuSufei ZhengZhanyu WangSihui WangXinfeng WangLu YangHaiyan XuZheng CaoXiaoli FengQi XueYan WangNan SunJie HePublished in: Cancer communications (London, England) (2022)
Our study elucidated the molecular mechanism by which KRAS-G12D mutation drives immunosuppression and enhances resistance of ICIs in NSCLC. Importantly, our findings demonstrate that ICIs in combination with chemotherapy may be more effective in patients with KRAS-G12D-mutant NSCLC.